Every NR4A2 paper, in plain English

Contexts for dopamine specification by calcium spike activity in the CNS.

Velázquez-Ulloa NA, Spitzer NC, Dulcis D

This study uses frog embryos to show that early electrical activity in developing neurons influences whether they become dopamine-producing cells, depending on their specific molecular environment. It identifies distinct subpopulations of neurons with different responses to this activity and suggests these mechanisms could inform future methods for growing replacement neurons in the lab.

• Early electrical spikes help determine if developing neurons become dopamine-producing.
• Different brain regions respond differently to changes in this electrical activity.
• Neurons already expressing GABA are most likely to switch to dopamine production.
• Findings may guide protocols for creating replacement neurons from stem cells.

Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.

Ramirez-Herrick AM, Mullican SE, Sheehan AM, Conneely OM

Reducing the dosage of NR4A1 and NR4A3 in mice causes blood cancers resembling myelodysplastic/myeloproliferative neoplasms. This study identifies specific genes involved in this process but does not address NR4A2 or human neurological conditions.

• The study focuses on NR4A1 and NR4A3, not the NR4A2 gene relevant to your child.
• Researchers used mice to model blood cancers, not neurological disorders.
• No findings apply to human patients or current treatments for NR4A2 syndrome.

The nuclear orphan receptor Nr4a2 induces Foxp3 and regulates differentiation of CD4+ T cells.

Sekiya T, Kashiwagi I, Inoue N, Morita R, Hori S, Waldmann H, Rudensky AY, Ichinose H, Metzger D, Chambon P, Yoshimura A

This study identifies Nr4a2 as a key regulator of immune system balance, specifically controlling the development and function of regulatory T cells that prevent inflammation. It demonstrates that Nr4a2 directly activates Foxp3 to maintain these protective immune cells and prevents harmful inflammatory responses.

• Nr4a2 directly binds to and activates the Foxp3 gene in immune cells.
• Nr4a2 promotes regulatory T cell development and suppressive function.
• Loss of Nr4a2 leads to increased inflammation and colitis in models.
• The research focuses on immune tolerance rather than neurological function.

Retinoid X receptor α acts as a negative regulator in Nurr1-induced dopaminergic differentiation in rat neural precursor cells.

Yoon EH, Lee KJ, Kim YS, Chang MS, Lee SH, Park CH

RXRα suppresses the ability of Nurr1 to promote dopaminergic neuron development in rat neural precursor cells. This interaction reduces the activity of the TH promoter, which is critical for dopamine production.

• RXRα acts as a negative regulator of Nurr1-induced dopaminergic differentiation.
• Forced RXRα expression significantly reduces Nurr1 activity in rat neural precursor cells.
• The RXRα-Nurr1 heterodimer represses tyrosine hydroxylase promoter activity.
• Disrupted dimeric binding alters this regulatory repression mechanism.

Retinoid X receptor α acts as a negative regulator in Nurr1-induced dopaminergic differentiation in rat neural precursor cells.

This study shows that Retinoid X receptor alpha suppresses the ability of Nurr1 to help rat neural precursor cells become dopamine-producing neurons. The findings are limited to rat cell cultures and do not provide direct evidence for human treatment strategies.

• Retinoid X receptor alpha inhibits Nurr1-driven dopaminergic differentiation in rat cells.
• The research uses rat neural precursor cells, not human tissue or patients.
• No clinical data or human genetic findings are presented.
• The mechanism is preclinical and does not suggest an immediate therapy.

Potential sources of stem cells as a regenerative therapy for Parkinson's disease.

El-Sadik AO

This review outlines various stem cell sources, including embryonic, adult neural, and induced pluripotent cells, that can differentiate into dopamine neurons for potential Parkinson's disease therapy. It highlights the specific transcription factors required for this development but does not provide clinical data or direct treatment options for NR4A2-related syndromes.

• Stem cells can generate dopamine neurons using specific signaling factors like sonic hedgehog and Wnt 1.
• Adult neural stem cells offer neuroprotective benefits alongside neuron replacement potential.
• Induced pluripotent and bone marrow stem cells serve as reliable alternatives to embryonic sources.
• The paper reviews preclinical protocols without human clinical trial results or NR4A2-specific findings.

Development of cortical malformations in BCNU-treated rat, model of cortical dysplasia.

Moroni RF, Cipelletti B, Inverardi F, Regondi MC, Spreafico R, Frassoni C

This study uses a rat model to show how prenatal brain injury disrupts the scaffolding that guides neurons to their correct positions, leading to cortical malformations. It identifies specific structural defects in glial fibers and cell migration as the cause of these developmental errors.

• Prenatal BCNU exposure in rats mimics human cortical dysplasia features.
• Disrupted radial glia and tangential fibers prevent proper neuronal migration.
• Neurons form heterotopias with abnormal pseudo-laminar structures.
• GABAergic cell distribution is altered from embryonic stages.

A simple method for large-scale generation of dopamine neurons from human embryonic stem cells.

Morizane A, Darsalia V, Guloglu MO, Hjalt T, Carta M, Li JY, Brundin P

Researchers develop a simplified, reproducible method to generate large quantities of dopamine neurons from human embryonic stem cells for potential use in Parkinson's disease research and transplantation. The protocol produces midbrain-type dopamine neurons that retain their ability to produce dopamine even after cryopreservation and repeated passaging.

• The new protocol is simpler and more reliable than previous methods for creating dopamine neurons from stem cells.
• Expanded progenitor cells maintain their dopaminergic phenotype after freezing and thawing.
• Generated neurons express key midbrain markers like Nurr1, Lmx1a, and Aldh1a.
• This method supports drug screening and disease mechanism studies but does not test treatments in patients.

Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease.

Bousquet M, Gue K, Emond V, Julien P, Kang JX, Cicchetti F, Calon F

Increasing omega-3 fatty acids in mice does not protect against Parkinson's-like damage unless the levels are raised significantly through direct dietary supplementation. The study shows that endogenous conversion of fats is insufficient for neuroprotection, highlighting the need for high-dose supplements rather than relying on natural metabolic processes.

• Endogenous omega-3 production in mice fails to protect against Parkinson's toxin damage.
• Dietary DHA supplementation proves more effective than genetic conversion for neuroprotection.
• Higher brain DHA levels correlate with preserved dopamine neuron markers.
• The study uses a mouse model, not human participants or NR4A2 genetics.

The orphan nuclear receptor Nurr1 restricts the proliferation of haematopoietic stem cells.

Sirin O, Lukov GL, Mao R, Conneely OM, Goodell MA

Nurr1 (NR4A2) regulates blood stem cell quiescence by inhibiting proliferation through the p18 protein. This study focuses on hematopoietic stem cells in mice and does not address neurological or developmental outcomes relevant to NR4A2 syndrome.

• Nurr1 forces blood stem cells into a dormant, non-dividing state.
• Reduced Nurr1 levels cause these stem cells to proliferate abnormally.
• The mechanism involves upregulation of the cell-cycle inhibitor p18.
• Research uses mouse models and cell lines, not human patients.
• Findings relate to blood system regulation, not brain development.

The corticofugal neuron-associated genes ROBO1, SRGAP1, and CTIP2 exhibit an anterior to posterior gradient of expression in early fetal human neocortex development.

Ip BK, Bayatti N, Howard NJ, Lindsay S, Clowry GJ

This study maps the normal developmental timeline of gene expression in the human fetal neocortex, identifying when specific markers appear as the motor cortex forms. It provides baseline anatomical data on cortical layering but does not investigate NR4A2 function or disease mechanisms.

• ROBO1, SRGAP1, and CTIP2 show high anterior expression in early fetal neocortex development.
• These markers help identify the early location of the human motor cortex between 8-15 weeks.
• NURR1 appears later as a marker for Layer VI neurons during cortical formation.
• The paper describes normal neurodevelopmental gradients without addressing NR4A2-related syndromes.

Expression of Nurr1 during rat brain and spinal cord development.

Li Y, Cong B, Ma C, Qi Q, Fu L, Zhang G, Min Z

This study maps when and where the Nurr1 protein appears in developing rat brains and spinal cords. It shows that Nurr1 is present in immature, migrating nerve cells but disappears as those cells mature into adult tissue.

• Nurr1 levels rise during embryonic development in rats.
• The protein marks immature, migrating nerve cells.
• Nurr1 expression drops sharply after birth.
• Mature adult rat brains and spinal cords lack Nurr1.
• Nurr1 is absent from proliferating (dividing) cells.

Selective regulation of nuclear orphan receptors 4A by adenosine receptor subtypes in human mast cells.

Zhang L, Paine C, Dip R

This study investigates how adenosine signaling regulates NR4A2 expression in human mast cells, which are immune cells involved in allergic and inflammatory responses. The research identifies a specific molecular pathway involving adenosine receptors and kinase activity that controls NR4A2 levels in these non-neuronal cells. This work does not provide information on NR4A2's role in brain development or potential treatments for NR4A2-related syndromes.

• NR4A2 expression increases in human mast cells when exposed to adenosine analogues.
• Specific adenosine receptor subtypes modulate NR4A2 induction via kinase pathways.
• The study focuses on immune cell inflammation, not neurological function.
• No findings relate to dopaminergic neurons or neurodevelopmental phenotypes.

Replicated association of the NR4A3 gene with smoking behaviour in schizophrenia and in bipolar disorder.

Novak G, Zai CC, Mirkhani M, Shaikh S, Vincent JB, Meltzer H, Lieberman JA, Strauss J, Lévesque D, Kennedy JL, Le Foll B

Variants in the NR4A3 gene are linked to heavier smoking in people with schizophrenia and bipolar disorder, suggesting a genetic connection between this gene and nicotine addiction in individuals with these mental health conditions.

• NR4A3 gene variants are tied to heavier smoking in schizophrenia and bipolar disorder
• The link was confirmed in two separate patient groups
• NR4A3 may influence nicotine addiction in people with mental health conditions
• This gene is involved in dopamine-related brain pathways

VEGF stimulates PKD-mediated CREB-dependent orphan nuclear receptor Nurr1 expression: role in VEGF-induced angiogenesis.

Zhao D, Desai S, Zeng H

VEGF triggers the production of Nurr1 in blood vessel cells through a specific signaling pathway involving CREB and protein kinase D, and Nurr1 is essential for VEGF-driven blood vessel growth. This process is critical for tumor blood vessel formation and may offer a target for blocking cancer progression.

• VEGF boosts Nurr1 levels in blood vessel cells
• CREB and protein kinase D control Nurr1 production
• Nurr1 is needed for VEGF-driven blood vessel growth
• Blocking Nurr1 stops vessel formation in lab tests

Maternal vitamin D deficiency alters the expression of genes involved in dopamine specification in the developing rat mesencephalon.

Cui X, Pelekanos M, Burne TH, McGrath JJ, Eyles DW

Maternal vitamin D deficiency in rats reduces the expression of Nurr1, a gene critical for developing dopamine-producing neurons. This suggests that environmental factors during pregnancy can disrupt the genetic pathways necessary for proper brain development.

• Rat embryos with maternal vitamin D deficiency show reduced Nurr1 levels.
• Nurr1 is essential for specifying dopaminergic neuron development.
• Other key developmental genes like Lmx1b remain unaffected.
• Reduced specification factors may alter dopamine neuron formation.
• Findings link prenatal environment to neurodevelopmental signaling changes.

Identification of NURR1 as a mediator of MIF signaling during chronic arthritis: effects on glucocorticoid-induced MKP1.

Ralph JA, Ahmed AU, Santos LL, Clark AR, McMorrow J, Murphy EP, Morand EF

This study shows that NURR1 helps regulate inflammation in rheumatoid arthritis by controlling how cells respond to steroid medications. It identifies a specific molecular pathway where MIF signaling reduces the effectiveness of steroids, but this mechanism is unrelated to NR4A2-related syndromes.

• NURR1 regulates glucocorticoid sensitivity in rheumatoid arthritis fibroblasts.
• MIF signaling reduces steroid-induced anti-inflammatory mediator MKP1 via NURR1.
• This mechanism is specific to chronic inflammation and arthritis models.
• The findings do not address NR4A2-related neurological or developmental syndromes.

In vitro differentiation of human amniotic fluid-derived cells: augmentation towards a neuronal dopaminergic phenotype.

Pfeiffer S, McLaughlin D

Human amniotic fluid cells differentiate into neurons and express dopaminergic markers in laboratory dishes, with the key Parkinson's-related protein NURR1 decreasing during this process. This study demonstrates that these specific stem-like cells have an inherent potential to become dopamine-producing neurons when exposed to standard growth factors. The findings provide basic biological data on cell behavior but do not test treatments or outcomes in humans.

• Amniotic fluid cells naturally express neuronal and dopaminergic markers like TH and NURR1.
• Standard lab induction protocols increase neuronal marker expression and change cell shape.
• NURR1 protein levels decrease when these cells are induced to become neurons.
• The study uses only in vitro cell cultures with no animal or human testing.
• Results show basic cellular potential without clinical application or treatment efficacy data.

Stem cell potential in Parkinson's disease and molecular factors for the generation of dopamine neurons.

Kim HJ

This review outlines the molecular factors required to generate dopamine neurons from stem cells for potential Parkinson's disease treatment. It details how specific genes, including Nurr1, guide this developmental process.

• Stem cells can potentially replace lost dopamine neurons in Parkinson's disease.
• Deriving midbrain dopamine neurons from stem cells remains technically challenging.
• Nurr1 is a critical molecular factor for dopamine neuron generation and survival.
• The paper reviews various stem cell types for future cell replacement therapies.

NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology.

Zhao Y, Bruemmer D

This review describes NR4A2 as a ligand-independent transcription factor that regulates metabolism, inflammation, and vascular remodeling. It outlines the molecular biology of the NR4A subfamily without addressing neurological function or clinical outcomes for patients with NR4A2-related syndromes.

• NR4A2 functions as a ligand-independent transcription factor in metabolic and vascular pathways.
• The review covers glucose homeostasis, adipogenesis, and inflammation rather than brain development.
• No clinical data, patient phenotypes, or treatment strategies for NR4A2 syndrome are presented.

Rapid increase of Nurr1 mRNA expression in limbic and cortical brain structures related to coping with depression-like behavior in mice.

Rojas P, Joodmardi E, Perlmann T, Ogren SO

Stress triggers a rapid increase in Nurr1 gene activity across multiple brain regions in mice, which appears to help the brain cope with acute stress. This response occurs alongside reduced dopamine levels in key areas, suggesting Nurr1 may act as a compensatory mechanism for dopamine transmission changes.

• Nurr1 mRNA rises quickly in mouse brains after acute stress exposure.
• The increase spans cortical, hippocampal, and midbrain regions within hours.
• Dopamine levels drop in the prefrontal cortex and midbrain during this stress response.
• Reduced Nurr1 expression previously linked to increased immobility and memory deficits in mice.
• Findings suggest Nurr1 helps counteract stress-induced dopamine changes.

beta-Amyloid disrupts activity-dependent gene transcription required for memory through the CREB coactivator CRTC1.

España J, Valero J, Miñano-Molina AJ, Masgrau R, Martín E, Guardia-Laguarta C, Lleó A, Giménez-Llort L, Rodríguez-Alvarez J, Saura CA

Beta-amyloid disrupts memory by blocking the CRTC1 pathway, which leads to reduced expression of NR4A2 and other genes essential for synaptic function. This mechanism links Alzheimer's pathology to specific molecular deficits in gene transcription required for learning.

• Beta-amyloid impairs CRTC1-dependent gene transcription in neurons.
• NR4A2 expression decreases alongside other memory-related genes like Bdnf.
• Reduced calcium influx drives this disruption via calcineurin inhibition.
• Restoring CRTC1 activity reverses transcriptional deficits in mouse models.

Characterization of axon guidance cue sensitivity of human embryonic stem cell-derived dopaminergic neurons.

Cord BJ, Li J, Works M, McConnell SK, Palmer T, Hynes MA

Human embryonic stem cell-derived dopaminergic neurons respond to axon guidance cues like Netrin-1 and Slit-2 as they mature in culture. This responsiveness persists even when exposed to pro-inflammatory cytokines found in diseased brains.

• hESC-derived dopaminergic neurons express receptors for Netrin-1 and Slit-2.
• Neurons show increased sensitivity to Netrin-1 as they mature in culture.
• Responses remain intact despite exposure to pro-inflammatory cytokines.
• This confirms these lab-grown neurons can integrate with host tissue pathways.

Genome-wide gene expression profiling of the Angelman syndrome mice with Ube3a mutation.

Low D, Chen KS

This study identifies reduced levels of the NR4A2 protein in a mouse model of Angelman syndrome, linking UBE3A deficiency to specific molecular changes. It does not provide evidence for treatments or clinical outcomes relevant to children with NR4A2-related syndromes.

• NR4A2 protein levels decrease in the cerebellum of Angelman syndrome mice.
• UBE3A deficiency directly correlates with lower NR4A2 expression in cell models.
• The research focuses on Angelman syndrome, not NR4A2-related disorders.
• No clinical data or therapeutic strategies for NR4A2 patients are presented.

Future directions for immune modulation in neurodegenerative disorders: focus on Parkinson's disease.

Maguire-Zeiss KA, Federoff HJ

This review discusses how the protein Nurr1 helps protect dopamine neurons by reducing brain inflammation and promoting cell survival. It highlights potential strategies to treat Parkinson's disease by targeting these immune pathways.

• Nurr1 reduces neuroinflammation in Parkinson's disease models.
• The protein stimulates vasoactive intestinal peptide for neuron survival.
• Nurr1 suppresses pro-inflammatory cytokines in glial cells.
• This is a theoretical review of immune modulation strategies.

Response to methadone maintenance treatment is associated with the MYOCD and GRM6 genes.

Fonseca F, Gratacòs M, Escaramís G, De Cid R, Martín-Santos R, Fernández-Espejo E, Estivill X, Torrens M

This study finds no significant link between NR4A2 gene variants and response to methadone treatment for opioid dependence. The research focuses on pharmacogenetics in a specific adult patient population, offering no direct insight into NR4A2-related syndromes or potential therapies.

• NR4A2 variant rs1405735 shows no significant association with methadone treatment response.
• The study examines opioid dependence, not NR4A2-related developmental syndromes.
• Significant findings involve MYOCD and GRM6 genes, not NR4A2.
• Results are preclinical in relevance to pediatric neurodevelopmental conditions.

[Nurr1 and its potential use in diagnosis and gene therapy for PD].

Yang S, Lu LL, Yang H

This review discusses the biological role of Nurr1 in Parkinson's disease and proposes its potential application in diagnosis and gene therapy. It does not provide specific data, clinical outcomes, or treatment protocols relevant to NR4A2-related developmental syndromes.

• The paper is a theoretical review without an abstract or specific study data.
• It focuses on Parkinson's disease rather than NR4A2 neurodevelopmental disorders.
• No human clinical evidence or patient-specific findings are presented.
• Gene therapy concepts are mentioned but lack preclinical proof of concept for this condition.

Nurr1 regulates RET expression in dopamine neurons of adult rat midbrain.

Galleguillos D, Fuentealba JA, Gómez LM, Saver M, Gómez A, Nash K, Burger C, Gysling K, Andrés ME

This study confirms that the Nurr1 protein directly controls RET gene expression in adult dopamine neurons. Reducing Nurr1 levels in rats significantly lowers both RET mRNA and protein, while leaving other key dopamine markers unchanged.

• Nurr1 regulates RET expression in adult rat midbrain dopamine neurons.
• Knocking down Nurr1 reduces RET mRNA by nearly 77% and protein by 47%.
• Other dopamine markers like tyrosine hydroxylase remain stable when Nurr1 is reduced.
• Nurr1 directly induces the human RET promoter in a concentration-dependent manner.

Cytokines induce NF-κB, Nurr1 and corticotropin-releasing factor gene transcription in hypothalamic 4B cells.

Kageyama K, Kagaya S, Takayasu S, Hanada K, Iwasaki Y, Suda T

Inflammatory signals in the brain activate stress-response genes through a pathway involving Nurr1. This study demonstrates how immune molecules interact with Nurr1 to regulate corticotropin-releasing factor, a key driver of the body's stress response.

• Cytokines stimulate Nurr1 and NF-kappaB activity in hypothalamic cells.
• This pathway directly increases the transcription of the CRF gene.
• The findings link immune signaling to neuroendocrine stress regulation via Nurr1.
• The study uses cell lines, not human patients or animal models.

Minireview: Nuclear hormone receptor 4A signaling: implications for metabolic disease.

Pearen MA, Muscat GE

This review summarizes how NR4A2 and related receptors regulate metabolism in tissues like liver and fat, noting that small molecules can activate them. It suggests these pathways might eventually help treat metabolic diseases such as obesity or diabetes.

• NR4A2 regulates lipid and energy balance in metabolic tissues.
• Small molecule agonists can activate NR4A receptors without natural ligands.
• Therapeutic potential focuses on metabolic disorders, not neurological conditions.
• Evidence comes from cell and animal studies of metabolism.

Assignment of the orphan nuclear receptor Nurr1 by NMR.

Michiels P, Atkins K, Ludwig C, Whittaker S, van Dongen M, Günther U

This study maps the physical structure of the Nurr1 protein to help researchers understand how it might interact with potential drugs. It identifies specific flexible regions in the protein that could be important for future drug design targeting Parkinson's disease or schizophrenia.

• Researchers mapped the atomic structure of the Nurr1 protein using NMR spectroscopy.
• About 84% of the protein residues were successfully assigned and characterized.
• Flexible regions near the ligand-binding pocket are identified as potential drug targets.
• This work supports basic research into small molecule therapies for Nurr1-related conditions.

Histamine modulation of peripheral CRH receptor type 1alpha expression is dependent on Ca(2+) signalling and NF-kappaB/p65 transcriptional activity.

Zocco D, McMorrow JP, Murphy EP

Histamine increases CRH-R1alpha expression in joint tissues through calcium signaling and NF-kappaB/p65 activation, which may worsen inflammation in autoimmune arthritis. This pathway involves direct binding of NF-kappaB/p65 to the CRH-R1 promoter and could be a target for reducing joint damage.

• Histamine boosts CRH-R1alpha in joint cells via calcium and NF-kappaB/p65
• NF-kappaB/p65 directly binds the CRH-R1 promoter to drive expression
• Blocking NF-kappaB or calcium signaling stops CRH-R1alpha increase
• Three NF-kappaB binding sites are essential for this effect
• This pathway may contribute to joint inflammation in autoimmune disease

Roles of db-cAMP, IBMX and RA in aspects of neural differentiation of cord blood derived mesenchymal-like stem cells.

Tio M, Tan KH, Lee W, Wang TT, Udolph G

This study shows that human cord blood stem cells can be coaxed to express markers of dopamine-producing neurons in a laboratory dish. The researchers identify specific chemical signals that influence these cellular changes, but the work remains entirely preclinical with no application to patients.

• Cord blood stem cells express dopamine neuron markers when treated with specific chemicals.
• The study uses only cell cultures, not animals or human patients.
• No treatment for NR4A2 syndrome or Parkinson's disease is tested or proposed.
• Findings describe basic molecular mechanisms without clinical relevance.

Endothelial cell activation in a VEGF-A gradient: relevance to cell fate decisions.

Akeson A, Herman A, Wiginton D, Greenberg J

Microvascular endothelial cells interpret small changes in VEGF-A levels to make fate decisions, with some genes responding to signal strength while others activate abruptly regardless of level. This reveals how subtle differences in growth factor signals can lead to distinct gene activity patterns during blood vessel development.

• VEGF-A gradients guide blood vessel cell decisions
• NR4A2 activates like a switch, ignoring signal level
• Some genes need precise VEGF-A levels to turn on
• Signal duration and strength are interpreted differently
• NR4A2 is not sensitive to VEGF-A concentration

Learning from nature: pregnancy changes the expression of inflammation-related genes in patients with multiple sclerosis.

Gilli F, Lindberg RL, Valentino P, Marnetto F, Malucchi S, Sala A, Capobianco M, di Sapio A, Sperli F, Kappos L, Calogero RA, Bertolotto A

Pregnancy naturally reduces inflammation in multiple sclerosis by normalizing the expression of several genes, including NR4A2, within the first trimester. This normalization correlates with fewer disease relapses, while a delay in this gene regulation is linked to higher relapse risk.

• NR4A2 expression normalizes during pregnancy in MS patients.
• Gene changes revert to pre-pregnancy levels after birth.
• Delayed normalization correlates with increased relapse risk.
• Study focuses on multiple sclerosis, not NR4A2 syndrome.

Regulation of aldosterone synthase by activator transcription factor/cAMP response element-binding protein family members.

Nogueira EF, Rainey WE

This study shows that NURR1 (NR4A2) works together with other proteins to increase the activity of the gene responsible for producing aldosterone, a hormone involved in blood pressure regulation. The research demonstrates this interaction using human adrenal cell lines and molecular assays rather than clinical patient data.

• NURR1 synergizes with ATF/CREB proteins to boost aldosterone synthase gene activity.
• The study uses human adrenal cell lines, not patients or animal models.
• Findings relate to hormone regulation, not the neurological symptoms of NR4A2 syndrome.
• No clinical treatments or patient outcomes are reported in this work.

Identification of microRNAs regulated by activin A in human embryonic stem cells.

Tsai ZY, Singh S, Yu SL, Kao LP, Chen BZ, Ho BC, Yang PC, Li SS

This study identifies how the signaling molecule activin A alters gene expression in human embryonic stem cells, specifically noting that NR4A2 levels change in response to this treatment. The research maps out a complex network of microRNAs and target genes involved in maintaining stem cell pluripotency and self-renewal.

• Activin A changes the expression profile of specific microRNAs in human embryonic stem cells.
• NR4A2 is identified as a target gene regulated by these activin-induced microRNAs.
• The study focuses on stem cell self-renewal mechanisms rather than disease pathology.
• No clinical data or patient outcomes are reported in this preclinical molecular biology work.

Trans-10,cis-12-CLA dysregulate lipid and glucose metabolism and induce hepatic NR4A receptors.

Navarro MA, Badimon L, Rodriguez C, Arnal C, Noone EJ, Roche HM, Osada J, Martinez-Gonzalez J

The t10,c12 isomer of conjugated linoleic acid (CLA) worsens blood sugar and fat metabolism in mice by increasing levels of NR4A receptors in the liver, which are linked to insulin resistance and fatty liver. This effect was not seen with the c9,t11-CLA isomer, which had neutral or beneficial metabolic effects.

• t10,c12-CLA disrupts glucose and fat metabolism
• t10,c12-CLA increases NR4A receptors in the liver
• NR4A receptor rise correlates with fatty liver and insulin issues
• c9,t11-CLA does not cause these changes
• NR4A receptors may be key drivers of metabolic problems

Delayed dopaminergic neuron differentiation in Lrp6 mutant mice.

Castelo-Branco G, Andersson ER, Minina E, Sousa KM, Ribeiro D, Kokubu C, Imai K, Prakash N, Wurst W, Arenas E

Lrp6 mutations delay the development of dopamine-producing neurons in mice without preventing their formation entirely. This suggests that Lrp6 helps time the onset of dopaminergic neuron differentiation during early brain development.

• Lrp6 mutant mice show delayed dopamine neuron differentiation, not absence.
• Midbrain patterning and cell survival remain normal in these mutants.
• Dopamine markers like Nurr1 and Pitx3 are temporarily reduced.
• The study uses mouse models, not human patients or clinical data.

The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives.

Wan F, Lenardo MJ

This review describes how the transcription factor NF-kappaB is regulated inside the cell nucleus, identifying various proteins that influence its activity. It mentions Nurr1 (NR4A2) as one of many nuclear regulators of NF-kappaB but does not focus on NR4A2 biology or function. The paper provides general background on immune and cellular signaling rather than specific insights into NR4A2-related syndromes.

• NF-kappaB regulates cell growth, death, and immune responses through nuclear signaling.
• Nurr1 is listed as a nuclear regulator of NF-kappaB transcriptional activity.
• The paper reviews general mechanisms of NF-kappaB regulation in the nucleus.
• No specific findings regarding NR4A2 mutations or related neurological conditions are presented.